Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10)
NCT06822790Phase 3Active, not recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Jul 2028
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 24
01
Overview
Phase 3, open-label, single-arm trial of plozasiran in hypertriglyceridemia, sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events at 24 months. Started Apr 2025; status: active, not recruiting.
02
Drugs
plozasiran
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT06822790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06822790.